| Prev Close | 88.42 |
| Open | 88.42 |
| Day Low/High | 88.11 / 90.33 |
| 52 Wk Low/High | 82.51 / 120.53 |
| Volume | 1.79M |
Horizon Therapeutics Public Limited Company (HZNP)
89.34
0.92
1.04
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 229.17B |
| Market Cap | 21.29B |
| P/E Ratio | 19.63 |
| Div & Yield | N.A. (N.A) |
Latest News
A Market in Transition
Now's the time to take a step back and prepare mentally for what happens next.
The Market Is Shrugging Off the Political News
And that is helping to create fear of missing out.
'Nervous' Market Waits for More Stimulus News
I've made a few new buys Thursday morning.
Market Has to Deal With Earnings Before Any Election Drama
There a several names that I expect to see strong earnings results from.
Here's How I'm Positioning Myself Into the Surprise Gap Up
While I'm reducing some of my bigger positions into strength, I'm definitely not bearish.
Traders Focused on Bounces Have Made Some Quick Exits Already
This isn't a market with a lot of very extended stocks so the chances of catching some names at support are good.
This Is Great Action for Stock Pickers Right Now
Stick to themes like biotechnology, SPACs, EV batteries, and others.
My Shopping List Amid This Selloff
Don't be in a rush. The key to accumulating stocks in this environment is to move incrementally.
The Indices Are Doing a Poor Job of Reflecting What's Really Going On
Here are several names I'm looking to build on further weakness.
Reactive Bulls Are Still Topping Anticipatory Bears
There are some concerns in the price action but dip buyers keep stepping up very quickly.
Celebrating the Greatness of Individual Traders
Good individual traders will produce returns far in excess of anything that traditional Wall Street will earn.
VMware and Chevron Are Among 11 Well-Known Stocks Ready to Change Direction
These names are showing bullish and bearish technical patterns over the past week.
Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers
The Dublin firm on Nov. 6 unveiled third-quarter numbers that topped analysts' estimates and raised its full-year net sales outlook and the lower end of its 2017 adjusted Ebitda guidance.
Closing Bell: Volatility at Lowest Since 1993; Pershing Backs Howard Hughes
Volatility sank to its lowest level since 1993 to begin the new week as indexes held close to their flatlines.
Bears Are Losing Their Grip on Horizon Pharma
The stock is slowly building a bullish setup.
Horizon Pharma Tanks on Failed Late-Stage Study
Horizon's nueromuscular disorder treatment trials failed.
How Do the Charts Look for Jim Cramer's Weekly Shopping List?
No matter who wins the election, there are ways to make money.
Closing Bell: Fed's Brainard Cautions 'Prudence'; U.S. Stocks Soar
Relief flooded Wall Street after a number of Fed speakers took a dovish turn following increasingly hawkish rhetoric.
Tweets on the Street: Pimco's Eurozone Concerns, Shkreli on Horizon Pharma
Social media chatter also included takes by Michael Bloomberg and Warren Buffett on small-business success.
A Move Lower Is on the Horizon (Pharma)
Don't be surprised if HZNP trends lower to next chart support around $10.
Horizon Pharma Needs a Health Check
HZNP could work lower to $10 in the weeks and months ahead.
Cramer: Collateral Damage Is Giving These Stocks a Bad Name
But for the brave, they could offer a solid bottom-fishing opportunity.
Jim Cramer Recommends Ford Over General Motors Among Autos
Automakers are reporting sales results today, and Ford is Jim Cramer’s top pick in the auto sector.
Silly Season Continues for Biotech
Valuations of some small-cap concerns, such as Relypsa, are ridiculously cheap.
